This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback
Trial record 6 of 8 for:    nnz-2566

A Safety Study of NNZ-2566 in Pediatric Rett Syndrome

This study has been completed.
Information provided by (Responsible Party):
Neuren Pharmaceuticals Limited Identifier:
First received: February 21, 2016
Last updated: February 7, 2017
Last verified: February 2017
The purpose of this study is to determine whether NNZ-2566 is safe and well tolerated in the treatment of Rett syndrome in children and adolescents.

Condition Intervention Phase
Rett Syndrome Drug: NNZ-2566 Drug: Placebo Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Double-blind, Placebo-controlled, Dose-ranging Study of the Safety and Pharmacokinetics of Oral NNZ-2566 in Pediatric Rett Syndrome

Resource links provided by NLM:

Further study details as provided by Neuren Pharmaceuticals Limited:

Primary Outcome Measures:
  • Adverse events [ Time Frame: Through study completion, an average of 11 weeks ]
    Incidence of adverse events (AEs), including serious adverse events (SAEs), will be compared across the three NNZ-2566 doses and placebo. SAEs and AEs will be examined throughout the study.

Secondary Outcome Measures:
  • Motor Behaviour Assessment Scale (MBA) [ Time Frame: Through study completion, an average of 11 weeks ]
  • Clinical Global Impression of Improvement (CGI-I) [ Time Frame: Through study completion, an average of 11 weeks ]
  • Caregiver Top 3 Concerns via a Visual Analogue Scale (VAS) [ Time Frame: Through study completion, an average of 11 weeks ]

Enrollment: 82
Actual Study Start Date: March 2016
Study Completion Date: January 2017
Primary Completion Date: January 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: NNZ-2566
Glycyl-L-2-Methylpropyl-L-Glutamic Acid
Drug: NNZ-2566
Glycyl-L-2-Methylpropyl-L-Glutamic Acid (NNZ-2566) supplied as a lyophilized powder for reconstitution with strawberry flavored solution 0.5% v/v in Water for Injection.
Other Name: trofinetide
Placebo Comparator: Placebo (strawberry flavored solution)
Strawberry flavored solution and Water for Injection
Drug: Placebo
Strawberry flavored solution and Water for Injection
Other Name: Strawberry flavoring

Detailed Description:

Rett syndrome is a neurodevelopmental disorder primarily affecting females. The disorder is characterized by apparent normal development in early infancy (6-18 months), followed by a period of regression with onset of systemic and neurological signs. The CNS symptoms of Rett syndrome include learning disability, autism symptomatology and epilepsy and these can be severe and highly debilitating. Affected individuals also show signs of autonomic dysfunction, reflected in cardiovascular and respiratory abnormalities. There is no currently effective treatment for Rett syndrome.

This study will investigate the safety, tolerability and blood pharmacokinetics of treatment with oral administration of NNZ-2566 at 50 mg/kg, 100 mg/kg, 200 mg/kg BID, or placebo BID, in children and adolescent females with Rett syndrome. The study also will also investigate measures of efficacy and biomarkers during treatment.


Ages Eligible for Study:   5 Years to 15 Years   (Child)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Diagnosis of classic/typical Rett syndrome with a documented mutation of the MeCP2 gene.
  • Age 5 - 15 years.
  • Weight at Screening and Baseline between 15.0 kg-100.0 kg (at least 15.0 kg and no greater than 100.0 kg).
  • Each subject must be able to swallow the study medication provided as a liquid solution, or via gastrostomy tube.

Exclusion Criteria:

  • Actively undergoing neurological regression
  • Abnormal QT interval, prolongation or significant cardiovascular history.
  • Current treatment with insulin.
  • Anti-convulsants with liver enzyme inducing effects.
  • Unstable seizure profile.
  • Excluded concomitant medications.
  • Current clinically significant (as determined by the investigator). cardiovascular, renal, hepatic, or respiratory disease.
  • Gastrointestinal disease which may interfere with the absorption, distribution, metabolism or excretion of the study medication.
  • History of, or current cerebrovascular disease or brain trauma.
  • History of, or current clinically significant endocrine disorder, e.g. hypo- or hyperthyroidism, or diabetes mellitus.
  • History of, or current, malignancy.
  • Significant hearing and/or visual impairments that may affect ability to complete the test procedures.
  • Allergy to strawberry.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT02715115

United States, Alabama
University of Alabama
Birmingham, Alabama, United States, 35233
United States, California
UCSF Benioff Children's Hospital Oakland
Oakland, California, United States, 94609
University of California, San Diego
San Diego, California, United States, 92093
United States, Colorado
Children's Hosptial Colorado
Aurora, Colorado, United States, 80045
United States, Illinois
Rush University Medical Center
Chicago, Illinois, United States, 60612
United States, Massachusetts
Boston Children's Hospital
Boston, Massachusetts, United States, 02115
United States, Minnesota
Gillette Children's Specialty Healthcare
St. Paul, Minnesota, United States, 55101
United States, Ohio
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, United States, 45229
United States, Pennsylvania
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, United States, 19104
United States, South Carolina
Greenwood Genetic Center
Greenwood, South Carolina, United States, 29646
United States, Tennessee
Vanderbilt University
Nashville, Tennessee, United States, 37235
United States, Texas
Baylor College of Medicine
Houston, Texas, United States, 77030
Sponsors and Collaborators
Neuren Pharmaceuticals Limited
Principal Investigator: Daniel Glaze, MD Baylor College of Medicine
Principal Investigator: Alan Percy, MD University of Alabama at Birmingham
Principal Investigator: Timothy Feyma, MD Gillette Children's Specialty Healthcare
Principal Investigator: Peter Heydemann, MD Rush University Medical Center
Principal Investigator: Jeff Neul, MD University of California, San Diego
Principal Investigator: Tim Benke, MD Children's Hospital Colorado
Principal Investigator: Mary Jones, MD UCSF Benioff Children's Hospital Oakland
Principal Investigator: Steve Skinner, MD Greenwood Genetic Center
Principal Investigator: Mustafa Sahin, MD Boston Children’s Hospital
Principal Investigator: Sarika Peters, PhD Vanderbilt University
Principal Investigator: Shannon Standridge Children's Hospital Medical Center, Cincinnati
Principal Investigator: Eric Marsh, MD Children's Hospital of Philadelphia
  More Information

Responsible Party: Neuren Pharmaceuticals Limited Identifier: NCT02715115     History of Changes
Other Study ID Numbers: Neu-2566-RETT-002
Study First Received: February 21, 2016
Last Updated: February 7, 2017

Keywords provided by Neuren Pharmaceuticals Limited:
Rett's syndrome
Rett disorder
Rett's disorder

Additional relevant MeSH terms:
Rett Syndrome
Pathologic Processes
Mental Retardation, X-Linked
Intellectual Disability
Neurobehavioral Manifestations
Neurologic Manifestations
Nervous System Diseases
Genetic Diseases, X-Linked
Genetic Diseases, Inborn
Heredodegenerative Disorders, Nervous System
Pharmaceutical Solutions processed this record on August 23, 2017